文献速递腹部CTMR

影像学预测结直肠癌肝转移化疗后完全缓解:MR成像与CT成像的比较

Use of Imaging to Predict Complete Response of Colorectal Liver Metastases after Chemotherapy: MR Imaging versus CT Imaging.
PubMed 文献 · Radiology · 2017-03-22

该回顾性研究纳入8家医院87例患者的393个化疗后消失的结直肠癌肝转移灶,比较增强CT与钆塞酸二钠增强肝脏MR成像(EOB MR)的诊断性能。EOB MR预测无肿瘤的阳性预测值为78.0%,显著高于增强CT的35.2%(P < .001);两者预测残留肿瘤的阳性预测值无显著差异(CT 86.0% vs EOB MR 83.8%,P = .330)。结论认为EOB MR成像在评估化疗后消失的结直肠癌肝转移方面优于增强CT。

要点

  • EOB MR预测化疗后消失病灶无肿瘤的阳性预测值为78.0%,显著高于增强CT的35.2%(P < .001)。
  • 增强CT预测残留肿瘤的阳性预测值为86.0%,与EOB MR的83.8%无显著差异(P = .330)。
  • 对化疗后消失的结直肠癌肝转移灶,EOB MR在确认无肿瘤方面优于增强CT。

核心结论

  • EOB MR成像在评估化疗后消失的结直肠癌肝转移方面优于增强CT成像。

研究设计与样本

  • 回顾性研究,8家医院87例患者共393个化疗后消失的结直肠癌肝转移灶,均后续接受手术;匿名影像数据和病例报告表送至中心审阅系统,由4名放射科医师独立审阅,数据随机分为A、B两组由2名独立阅片者判读。

诊断标准与关键数值

  • 无肿瘤的真实标准定义为切除病灶病理无肿瘤、未切除病灶术后1年内每3个月随访增强CT无原位复发;EOB MR预测无肿瘤阳性预测值78.0%(95%CI 63.68%, 87.74%),增强CT为35.2%(95%CI 25.11%, 46.79%),P < .001;增强CT预测残留肿瘤阳性预测值86.0%(95%CI 78.61%, 91.16%),EOB MR为83.8%(95%CI 77.50%, 88.67%),P = .330。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

Purpose To compare the diagnostic performances of contrast agent-enhanced computed tomography (CT) and gadolinium ethoxybenzyl diethylenetriamine pentaacetic acid-enhanced liver magnetic resonance (MR) imaging (referred to as EOB MR imaging) in the evaluation of disappearing colorectal liver metastases (CRLMs) after chemotherapy. Materials and Methods The eight institutional review boards approved this retrospective study and waived the requirement for informed consent. On the basis of retrospective searches in eight hospitals, 87 patients with 393 CRLMs, each patient with one or more CRLM that later disappeared on contrast-enhanced CT scans after chemotherapy, and subsequently underwent surgery for the CRLMs, were enrolled. The anonymized imaging data and case report forms were sent to the central review system and independently reviewed by four radiologists. All anonymized data were randomly allocated into two groups (groups A and B), which were read by two independent readers. True absence of tumor was defined as pathologic absence of tumor for resected lesions and no in situ recurrence within 1 year after surgery for lesions left unresected at each 3-month follow-up contrast-enhanced CT. Positive predictive values for absence of tumor and for residual tumor on contrast-enhanced CT and EOB MR images were compared by using a generalized estimating equation. Results Among 393 CRLMs, the positive predictive value for absence of tumor on EOB MR images (78.0%; 95% confidence interval [CI]: 63.68%, 87.74%) was significantly higher than that on contrast-enhanced CT scans (35.2%; 95% CI: 25.11%, 46.79%; P < .001). The positive predictive value for residual tumor on CT scans (86.0%; 95% CI: 78.61%, 91.16%) was higher than that on EOB MR images (83.8%; 95% CI: 77.50%, 88.67%) without statistical significance (P = .330). Conclusion EOB MR imaging was superior to contrast-enhanced CT imaging for assessment of disappearing CRLMs after chemotherapy. © RSNA, 2017 Online supplemental material is available for this article.

来源:Radiology,查看原文。版权归原作者所有。

引用

  1. Park MJ, Hong N, Han K, et al. Use of Imaging to Predict Complete Response of Colorectal Liver Metastases after Chemotherapy: MR Imaging versus CT Imaging. Radiology. 2017. PMID: 28327002. doi:10.1148/radiol.2017161619

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。